Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasmsRaajit K. Rampal, Ronald Hoffman, John Mascarenhas et al.|Blood Advances|2018Cited by 61
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 StudyVikas Gupta, Ronald Hoffman, Rebecca B. Klisovic et al.|Transplantation and Cellular Therapy|2018Cited by 59
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Heidi Kosiorek et al.|Blood|2018Cited by 45
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas, Robert S. Hoffman, Josef T. Prchal et al.|Blood|2016Cited by 28
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)Raajit K. Rampal, Ronald Hoffman, John Mascarenhas et al.|Blood|2016Cited by 14